Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

SkinCure Oncology Announces Delivery of Its 46th Image Guided Superficial Radiation Device for Skin Cancer Treatment

SkinCure Oncology
Posted on: 11 Jan 18

SkinCure Oncology, the world-wide leader in providing a turnkey model for the delivery of Superficial Radiation Therapy (SRT) for the treatment of non-melanoma skin cancers, today announces it has taken delivery of its 46th image guided superficial radiation therapy system. As the world-wide leader, SkinCure Oncology has partnered with quality-focused dermatologists and Mohs surgeons to bring cancer center level radiation therapy skin cancer treatment to physician offices. Through its physician partnerships, SkinCure Oncology has facilitated the treatment of more image guided superficial radiation therapy patients than any other group in the world.

SkinCure Oncology CEO, Kerwin Brandt, attributes SkinCure’s success to physicians and patients that are looking for an effective alternative treatment to surgical procedures. Brandt states, “that patients are surgically fatigued and are seeking solutions that are non-invasive, pain-free, convenient, safe and conducive to an active lifestyle.”

Steven Scott, the Company’s COO and a career-long radiation therapist, highlights that the quality and level of care delivered to patients through the SkinCure Oncology model is second to none. The SkinCure model incorporates the utilization of image guided technology, board certified radiation therapists and physicists, access to radiation oncologists, along with site management, and qualitative procedures and review protocols.

"Bringing each of these features together in a dermatology practice office moves the level of care to a premier cancer center level quality,” notes Scott, a former radiation therapist for MD Anderson.

SkinCure Oncology’s Chief Medical Officer, both a dermatologist and Mohs surgeon, as well as president elect of the American Osteopathic College of Dermatology (AOCD), Dr. Daniel Ladd highlights that given options, many patients strongly prefer SRT, as compared to other historical forms of treatment. In Ladd’s experience, he has seen curative treatment on par or better than other forms of treatment, along with superior cosmetic results.

As the company continues to facilitate access for patients to this preferred treatment method, it sees continued growth of its model, given the skin cancer epidemic being driven by the aging baby boomer population.

View source version on

Business Wire

Last updated on: 11/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.